Physician profile
Aaron Michael Bohrer
NPI 1548472079
$4,826.98
in general payments reported to CMS, 2019-2025
21 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $648 · 2021: $417 · 2022: $638 · 2023: $417 · 2024: $845 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,153.52 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $671.37 | 2022-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $360.64 | 2019-2023 | |
| Boston Scientific Corporation | $343.45 | 2023-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $291.14 | 2019-2024 | Camzyos |
| Paratek Pharmaceuticals, INC. | $263.09 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $238.91 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $237.20 | 2019-2025 | |
| Amgen INC. | $233.27 | 2021-2025 | Prolia, Evenity, Tepezza |
| Allergan, INC. | $204.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $186.18 | 2020-2024 | Fasenra |
| Abbvie INC. | $127.25 | 2021-2023 | Dalvance |
| Exact Sciences Corporation | $122.05 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $106.52 | 2019-2022 | |
| Gilead Sciences, INC. | $97.02 | 2024 | Veklury |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $76.17 | 2024 | Indigo System |
| Averitas Pharma INC. | $33.96 | 2024 | Qutenza |
| Lilly USA, LLC | $31.81 | 2023-2025 | Trulicity, Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $18.32 | 2021 | |
| Chiesi USA, INC. | $17.80 | 2020 | |
| La Jolla Pharmaceutical Company | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.